Select publications

assessment of her2

Hayes DF et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B. Clin Cancer Res 2001;7:2703-2711. Abstract

Hoang MP et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113(6):852-9. Abstract

Hung MC, Lau YK. Basic science of HER-2/neu: A review. Semin Oncol 1999;26(suppl 12):51-59. Abstract

Jacobs TW et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-1982. Abstract

Jacobs TW et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1 999; 17: 1983-1987. Abstract

Kakar S et al. Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu status in breast carcinoma. Molecular Diagnosis 2000;5:193-197. Abstract

Lebeau A et al. HER-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-363. Abstract

Mass RD et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials. Proc ASCO 2000;19: Abstract 291.

Mass RD et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc ASCO 2001;20: Abstract 291.

Onody P et al. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination. Application to node-negative breast cancer. Arch Pathol Lab Med 2001;125:46-750. Abstract

Pauletti G et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;21:3651-3664. Abstract

Ridolfi RL et al. HER-2/neu testing in breast carcinoma: A combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000;13:866-873. Abstract

Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001;12(suppl 1):S3- S8. Abstract

Schaller G et al. Current use of HER2 tests. Ann Oncol 2001;12(suppl 1):S97- S100. Abstract

Simon R et al. Patterns of HER-2/neu amplification and over-expression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93:1141-1146. Abstract

Thor A. HER2 - A discussion of testing approaches in the USA. Ann Oncol 2001;12(suppl 1):S101-S107. Abstract

Tubbs RR et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721. Abstract

role of trastuzumab in adjuvant and breast cancer

Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials. Oncology 2001;61(Suppl 2):14-21. Abstract

Bell R. Duration of therapy in metastatic breast cancer: Management using Herceptin. Anticancer Drugs 2001;12:561-8. Abstract

Burris HA 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28:38-44. Abstract

Cobleigh MA et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639- 2648. Abstract

Dieras V et al. Interaction between Herceptin and taxanes. Oncology 2001;61(Suppl 2):43-9. Abstract

Hortobagyi GN. Optimal duration of therapy with trastuzumab. Semin Oncol 2001;28:33-40. Abstract

Hortobagyi GN, Perez EA. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials. Semin Oncol 2001;28:41-6. Abstract

Leyland-Jones B. Dose scheduling - Herceptin. Oncology 2001;61(Suppl 2):31-6. Abstract

Leyland-Jones B, Smith I. Role of Herceptin in primary breast cancer: Views from North America and Europe. Oncology 2001;61(Suppl 2):83-91. Abstract

Leyland-Jones B et al. Pharmacologic insights into the future of trastuzumab. Ann Oncol 2001;12(Suppl 1):S43-S47. Abstract

Mass R et al. Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit. Breast Cancer Res Treat 2001; Abstract 522.

Mass R et al. Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization. Breast Cancer Res Tr e a t 2001; Abstract 18

Nabholtz JM, Slamon D. New adjuvant strategies for breast cancer: Meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). Semin Oncol 2001;28:1-12. Abstract

Perez EA. The role of adjuvant monoclonal antibody therapy for breast cancer: Rationale and new studies. Curr Oncol Rep 2001;3:516-22. Abstract

Robert NJ et al. Toxicity profiles: A comparative study of Herceptin (trastuzumab) and Taxol (paclitaxel) versus Herceptin, Taxol and carboplatin in HER2-positive patients with advanced breast cancer. Breast Cancer Res Tr e a t 2001; Abstract 529.

Seidman AD et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2 0 0 1 ; 1 9 : 2587-95. Abstract

Slamon D, Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001;28:13-9. Abstract

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J M e d 2001;344:783-792. Abstract

Sparano JA. Cardiac toxicity of trastuzumab (Herceptin): Implications for the design of adjuvant trials. Semin Oncol 2001;28:20-7. Abstract

Tripathy D et al. Effect of cardiac dysfunction on treatment outcome in the Herceptin (trastuzumab) pivotal trial. Breast Cancer Res Treat 2001; Abstract 525.

Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. Abstract

Vogel CL et al. Superior outcomes with Herceptin (trastuzumab) in fluorescence in situ hybridization (FISH)-selected patients. Proc ASCO 2001; Abstract 86.

Winer EP, Burstein HJ. New combinations with Herceptin in metastatic breast cancer. Oncology 2001;61(Suppl 2):50-7. Abstract

Home · Search